How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss working group of breast- and gynecopathologists

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Varga, Zsuzsanna ^a   Diebold, Joachim ^b   Dommann Scherrer, Corina ^c   Frick, Harald ^d   Kaup, Daniela ^e   Noske, Aurelia ^a   Obermann, Ellen ^f   Ohlschlegel, Christian ^g   Padberg, Barbara ^d   Rakozy, Christiane ^a   Oliver, Sara Sancho ^h   Schobinger Clement, Sylviane ^h   Schreiber Facklam, Heide ⁱ   Singer, Gad ^j   Tapia, Coya ^k   Wagner, Urs ^l   Mastropasqua, Mauro G ^m   Viale, Giuseppe ^m   Lehr, Hans Anton ⁿ  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Pathologische Institut am Kantonsspital Luzern   (Switzerland)

^c CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^d KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^e Liestal Hospital   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h Promed SA   (Switzerland)

ⁱ Institute of Pathology   (Germany)

^j Kantonsspital Baden   (Switzerland)

^k UNIVERSITY OF BERN   (Switzerland)

^l Unilabs Mittelland   (Switzerland)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GYNECOLOGIST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERRATER RELIABILITY; INTRARATER RELIABILITY; OBSERVATIONAL STUDY; PATHOLOGIST; TUMOR DIFFERENTIATION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM GRADING; OBSERVER VARIATION;

EID: 84861478152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037379     Document Type: Article

References (37)

1. Clarke M, Collins R, Darby S, Davies C, Evans V, et al. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, et al. (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784-1792.
3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144.
4. Shapiro CL, Recht A, (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344: 1997-2008.
5. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, et al. (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96: 1504-1513.
6. Urruticoechea A, Smith IE, Dowsett M, (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23: 7212-7220.
7. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, et al. (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-5575.
8. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
9. Gerdes J, Schwab U, Lemke H, Stein H, (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20.
10. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, et al. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329.
11. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, et al. (2011) Assessment of Ki76 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103: 1656-1664.
12. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
13. Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, et al. (2010) The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 23: 251-259.
14. Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, et al. (2009) Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 18: 135-141.
15. Zhang R, Chen HJ, Wei B, Zhang HY, Pang ZG, et al. (2010) Reproducibility of the Nottingham modification of the Scarff-Bloom-Richardson histological grading system and the complementary value of Ki-67 to this system. Chin Med J (Engl) 123: 1976-1982.
16. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
17. Grzybicki DM, Liu Y, Moore SA, Brown HG, Silberman JF, et al. (2001) Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 92: 2720-2726.
18. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, et al. (2002) Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198: 292-299.
19. Rezanko T, Akkalp AK, Tunakan M, Sari AA, (2008) MIB-1 counting methods in meningiomas and agreement among pathologists. Anal Quant Cytol Histol 30: 47-52.
20. Yamaguchi U, Hasegawa T, Sakurai S, Sakuma Y, Takazawa Y, et al. (2006) Interobserver variability in histologic recognition, interpretation of KIT immunostaining, and determining MIB-1 labeling indices in gastrointestinal stromal tumors and other spindle cell tumors of the gastrointestinal tract. Appl Immunohistochem Mol Morphol 14: 46-51.
21. Abramovich CM, Prayson RA, (1999) Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med 123: 793-800.
22. Weidner N, Moore DH 2nd, Vartanian R, (1994) Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 25: 337-342.
23. Biesterfeld S, Kluppel D, Koch R, Schneider S, Steinhagen G, et al. (1998) Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR. J Pathol 185: 25-31.
24. Offersen BV, Sorensen FB, Knoop A, Overgaard J, (2003) The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 43: 573-582.
25. Lehr HA, Hansen DA, Kussick S, Li M, Hwang H, et al. (1999) Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol 30: 1314-1320.
26. Makkink-Nombrado SV, Baak JP, Schuurmans L, Theeuwes JW, van der Aa T, (1995) Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study. Anal Cell Pathol 8: 227-245.
27. Molenaar WM, Plaat BE, Berends ER, te Meerman GJ, (2000) Observer reliability in assessment of mitotic activity and MIB-1-determined proliferation rate in pediatric sarcomas. Ann Diagn Pathol 4: 228-235.
28. Adams EJ, Green JA, Clark AH, Youngson JH, (1999) Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 52: 75-77.
29. Fandel TM, Pfnuer M, Schafer SC, Bacchetti P, Mast F, et al. (2008) Do we truly see what we think we see? The role of cognitive bias in pathological interpretation. J Pathol 216: 193-200.
30. Hamilton PW, van Diest PJ, Williams R, Gallagher AG, (2009) Do we see what we think we see? The complexities of morphological assessment. J Pathol 218: 285-291.
31. Ozcan A, Karslioglu Y, Kurt B, Onguru O, Gunhan O, (2007) Quantitative evaluation of immunohistochemical staining in gastrointestinal stromal tumors. Anal Quant Cytol Histol 29: 159-165.
32. Van Sandick JW, Baak JP, van Lanschot JJ, Polkowski W, ten Kate FJ, et al. (2000) Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's esophagus. J Pathol 190: 177-183.
33. Hasegawa T, Yamamoto S, Matsuno Y, (2002) Quantitative immunohistochemical evaluation of MIB-1 labeling index in adult soft-tissue sarcomas by computer-assisted image analysis. Pathol Int 52: 433-437.
34. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, et al. (1995) Assessment of the new prolifertion marker MIB-1 in breast carcinomas using image analysis: association with other prognostic factors and survival. Br J Cancer 71: 146-149.
35. Lehr HA, Hansen KD, Coltrera MD, Russ JC, Gown AM, (1996) Photoshop-based image analysis for the semiautomated assessment of Ki-67-defined proliferative activity in the routine diagnosis of breast cancer. Appl Immunohistochemistry 4: 117-127.
36. Menter DG, Hoque A, Motiwala N, Sahin AA, Sneige N, et al. (2001) Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. Anal Quant Cytol Histol 23: 218-228.
37. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J, (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receoptor, progesterone receptor, and Ki-67. Breast Cancer Res 12: R56.